Chirag PatelCo-Chief Executive Officer and President

Mr. Patel was Amneal’s Co-Founder and served as Co-Chairman and Co-Chief Executive Officer from 2002 to the completion of the combination with Impax Laboratories, Inc. in 2018. He served as a Co-Chairman of the Company’s Board since the combination. With his brother, Chintu Patel, Mr. Patel has also invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv Biosciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Earlier in his career, Mr. Patel co-founded technology companies NextGen Technologies and Veriprise Wireless. Mr. Patel also serves on the boards of the Liberty Science Center of New Jersey and New Jersey City University, and is a recipient of the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award®. Mr. Patel supports various philanthropic causes. Mr. Patel, together with his wife, Priti Patel, established the Niswarth International Foundation in 2013, which aims to bring fresh water, sanitation, nutrition and education to underprivileged children. Mr. Patel received his bachelor’s degrees in Commerce from H.A. College of Commerce, India, and in Business Administration from New Jersey City University. He also holds an honorary Doctorate of Humane Letters from New Jersey City University in recognition of his efforts to serve others.

Chintu PatelCo-Chief Executive Officer

Mr. Patel, R.Ph. most recently served as the Chief Executive Officer of Kashiv BioSciences and was Amneal’s Co-Founder and served as Co-Chairman of Amneal from 2002 to the completion of the combination with Impax Laboratories, Inc. in 2018. He served as a Co-Chairman of the Company’s Board since the combination. With his brother, Chirag Patel, Mr. Patel also co-founded and invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv BioSciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Before founding Amneal, Mr. Patel was a pharmacist and senior-level manager with Eckerd Pharmacy from 1994 to 2002, where he won numerous awards. Mr. Patel has been a featured speaker at the Hauppauge Industrial Association in New York and serves on the boards of the Long Island Association, Long Island University, and the Make-a-Wish Foundation®, and is a recipient of the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award®. Mr. Patel and his wife, Falguni Patel, run the Irada International Foundation, which focuses on health, education, and community outreach projects in India and the United States. Mr. Patel holds a bachelor’s degree in Pharmacy from Rutgers College of Pharmacy.

Andrew S. BoyerExecutive Vice President, Commercial Operations

Andy most recently served as President and CEO of North America Generics, Teva Pharmaceuticals, Inc.  Prior to joining Teva, Andy was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan plc (formerly, Actavis plc; formerly, Watson Pharmaceuticals, Inc.) since September 2006. He joined then Watson in 1998 as Associate Director of Marketing in Generics. Before joining Watson, Andy served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines. Andy received his Bachelor’s degree in Business Administration and Management from State University of New York at Albany.

Robert L. Iser, M.S.Senior Vice President, Global Quality Management

Bob is responsible for global quality management at Amneal and has more than 20 years of U.S. FDA and biopharmaceutical industry experience in product development, manufacturing, quality systems, policy and procedure development and validation of analytical methods. Prior to joining Amneal, Bob served as Vice President, Regulatory Consulting Services for Parexel International, where he led the Strategic Compliance Team advising clients on developing global regulatory strategies. He is also a former 14-year veteran of the U.S. FDA/Center for Drug Evaluation and Research (CDER). During his tenure with FDA, he served various leadership roles of increasing responsibility across several offices at the Center for Drug Evaluation and Research (CDER), including the Office of Pharmaceutical Quality, Office of Pharmaceutical Science, and Office of Generic Drugs (OGD). Prior to joining FDA, Bob served Quality Control leadership roles for Eurand, Inc. – at the time a privately held pharmaceutical company. He holds an M.S. in Chemistry from Wright State University and a B.S. in Chemistry from Muskingum College.

Sanjay JainPresident • India

Sanjay has oversight for all aspects of Amneal India operations, including managing the overall productivity and quality deliverables. He has extensive experience managing Operations, Validation and Quality, as well as Regulatory audits originating from the USFDA, MHRA, EU, TGA, Anvisa, MCC and Health Canada. Prior to joining Amneal, Sanjay held Quality and Operations positions at Ranbaxy Laboratories, Zydus Cadila, Torrent Pharmaceuticals, Cadila Pharmaceuticals, Intas Pharmaceuticals, Bharat Parenterals and Mesco Pharmaceuticals. He has developed quality systems, implemented various process improvement projects, developed and audited API vendor sites across the globe and successfully faced regulatory audits of various regulatory agencies multiple times. He is a member of the International Society for Pharmaceutical Engineering (ISPE) and Parenteral Drug Association (PDA and an accomplished speaker at various international conferences. He holds a degree in Pharmacy and a post graduate degree in Quality Management (Masters in Science, Quality Management).

Tasos KonidarisSenior Vice President, Chief Financial Officer

Tasos is responsible for leading Amneal’s global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Information Technology. He brings more than 30 years of corporate finance and leadership experience, including in the pharmaceutical and business analytics/data industries Tasos most recently served as Alcresta Therapeutics, Inc.’s Chief Financial Officer from 2016 to 2020, where he led the company’s finance, corporate development, information technology and human resources functions, and was instrumental in supporting the commercialization of a novel therapy to help critically ill patients and expand the company’s R&D pipeline. Prior to that, he served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria, Inc., from 2011 to 2015. In that role, he led finance and corporate development functions in delivering robust global organic growth as well as growth through licensing and acquisitions. Before joining Ikaria, Tasos served as Senior Vice President and Chief Financial Officer of Dun & Bradstreet Corporation for seven years, and previously held financial and general management roles of increasing responsibility at Schering-Plough Corporation, Pharmacia Corporation, Novartis Corporation and Bristol-Myers Squibb. He currently serves as a Director on the boards of Kadmon Holdings and Zep Inc. He holds a B.S. in Mathematics and Finance from Gwynedd Mercy University and an M.B.A. from Drexel University.

Stephen J. ManzanoSenior Vice President, General Counsel & Corporate Secretary

Steve is responsible for leading Amneal’s global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company’s corporate legal strategies to drive Amneal’s continued growth. He brings more than 25 years of experience in private corporate and financial transactional practice as well as leading in-house corporate legal teams in the pharmaceutical sector. Most recently, Steve concurrently served for 11 years as Group Vice President, General Counsel, Secretary & Head of Corporate Compliance for both Sun Pharmaceuticals and majority-owned subsidiary, Taro Pharmaceuticals Industries. Steve holds a Bachelor of Science degree in Public Administration & Political Science from James Madison University and a Juris Doctor degree from Tulane Law School.

Apurva SarafSenior Vice President, Corporate Development

Apurva leads Amneal’s Global Corporate Development function and is responsible for the company’s global strategic and business development initiatives. Apurva has been part of the extended executive leadership team since joining Amneal in 2012 and has broad experience in commercial operations across various channels and in negotiating and integrating M&A transactions globally. While at Amneal, Apurva also co-founded Gemini Laboratories, a successful specialty pharmaceuticals company. Prior to Amneal, Apurva served in positions of increasing responsibility, including head of North America business development, for Ranbaxy USA. Prior to Ranbaxy, Apurva was an equity analyst, with UBS, JPMorgan and Credit Suisse in New York, covering the Specialty and Generic Pharmaceuticals sector. Apurva completed his MBA in Finance from Baruch College in New York and Bachelor of Commerce in Economics and Accounting from Bombay University.

Nikita ShahSenior Vice President, Chief Human Resources Officer

Nikita oversees human resources for Amneal.  Prior to joining Amneal, Nikita led the internal audit and human resources functions for Warner Chilcott, a global specialty pharmaceutical company. She also supported corporate M&A, process improvements and systems efficiencies across the organization. Prior to Warner Chilcott, Nikita held roles of increasing responsibilities at AT&T and Deloitte Consulting.  Nikita received her master’s degrees in accounting and auditing from Gujarat University, India. She is a certified public accountant.

Joseph TodiscoSenior Vice President, Specialty Commercial

Joe has leadership responsibility for Specialty and International, as well as continued responsibility for the Amneal-Impax integration process. Joe joined Amneal six years ago as the head of Corporate Development and has been an integral part of the management team that executed the Amneal-Impax business combination, as well as multiple other business development, licensing and M&A transactions.  In addition to his role in Corporate Development, Joe held management oversight responsibility for Gemini Laboratories, building the company from inception to a highly profitable specialty pharmaceutical platform. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy’s North American Commercial Strategy and Business Development, and held various leadership roles with Par Pharmaceuticals. Prior to working in the pharmaceutical industry, Joe was an investment banker for Oppenheimer & Co. and also worked in financial services for Marsh & McLennan Companies.  Joe holds a bachelor’s degree in Economics from Georgetown University in Washington D.C. and an M.B.A. from Fordham Graduate School of Business in New York.